. 2014 Apr 24;176(3):320–326. doi: 10.1111/cei.12261

Table 2.

White blood cell counts and lymphocyte subsets in natalizumab-treated multiple sclerosis patients during the 41/48–month follow-up.

Cells median n/mmc (range)	Baseline	16–18 months	19–24 months	25–28 months	29–32 months	33–36 months	37–40 months	41–48 months
WBCs	5 900	8 300	9 600	8 800	8 400	9 200	8 100	9 200
WBCs	4 800–7 700	6 100–1 010	6 500–10 300	7 400–9 900	7 100–10 700	6 800–10 600	7 500–10 800	7 400–10 800
Lymphocytes	1 800	3 800	3 800	4 000	3 900	3 600	3 600	3 600
Lymphocytes	900–3 200	2 700–4 300	3 300–4 400	3 400–4 400	3 100–4 300	2 300–4 500	1 900–4 900	2 300–4 200
CD3⁺ (T cells)	1 030	2 040	2 100	2 400	2 450	2 400	2 200	2 000
CD3⁺ (T cells)	845–1 850	1 400–3 700	1 960–3 400	1 800–3 900	1 600–3 600	1 800–3 000	1 600–2 700	1 600–2 700
CD3⁺CD4⁺	800	1 300	1 600	1 700	1 500	1 500	1 550	1 400
CD3⁺CD4⁺	480–1 650	1 000–2 600	1 100–2 300	1 000–2 800	1 100–2 400	1 100–2 000	1 100–1 800	1 200–1 800
CD3⁺CD8⁺	370	820	810	860	860	850	800	760
CD3⁺CD8⁺	190–700	300–1 300	380–1 100	410–1 000	370–1 000	430–1 200	330–1 000	400–1 100
CD19⁺ (B cells)	240	860	830	800	850	780	710	700
CD19⁺ (B cells)	84–420	570–1 400	470–1 600	510–1 800	470–1 600	700–1 100	650–900	630–910
CD16⁺CD56⁺ (NK cells)	240	500	480	496	507	650	600	600
CD16⁺CD56⁺ (NK cells)	145–360	290–950	240–1 100	320–1 100	330–820	310–850	330–790	310–760
CD4/CD8 ratio	2·75	1·97	2·1	2·43	2·07	2·2	2·61	2·7
CD4/CD8 ratio	1·1–4·00	1·3–3·6	1·32–4·10	1·2–3·9	1·4–3·3	1·2–3·4	1·5–3·9	1·4–3·5

Median values indicated in bold.

NK = natural killer; WBCs = white blood cells.